First participants recruited to bipolar depression study at Oxford Health NHS Foundation Trust | Oxford Health NHS Foundation Trust

First participants recruited to bipolar depression study at Oxford Health NHS Foundation Trust | Oxford Health NHS Foundation Trust

The ASCEnD study aims to address the limited treatment options available for people experiencing depressive symptoms associated with bipolar disorder. The study compares the clinical and cost effectiveness of a combination of two drugs, aripiprazole and sertraline, in comparison to quetiapine, a commonly prescribed treatment for people with bipolar disorder experiencing depression. Source

It is estimated that between 1 and 2.5% of the French population is affected by bipolar disorder. However, it takes an average of 7 to 10 years before receiving appropriate treatment and care. Why is this disorder so often confused with depression, and what are the risks for patients? Interview with Professor Raoul Belzeaux, psychiatrist at Montpellier University Hospital.